[Variants of adenovirus type 5 with deletions in early genes: ability for selective replication in p53-defective human tumor cells].
Site-directed mutagenesis was used to construct human adenovirus serotype 5 (Ad5) variants defective in E1A or E1B. Mutant Adel3 with deletion from E1A was markedly attenuated in permissive cell cultures regardless of the p53 status, and replicated efficiently only in cells of the complementing 293 line. Mutant Adel2 with deletion from E1B55K infected the 293 line cells and p53-deficient human tumor cells (A431, SW480, HEp2) with efficiencies similar to those of Ad5, whereas its replication in normal p53-positive cells was substantially limited. Thus, Adel2 proved to be capable of selective infection and lysis of p53-deficient human tumor cells in vitro. On intratumor injection, Adel2 dramatically suppressed the growth of human epidermoid carcinoma (A431) in nude mice. Adel2 is thus a promising model for designing therapeutic agents against p53-deficient human tumors.
Institute of Molecular Biology, VECTOR State Research Center of Virology and Biotechnology, Kol'tsovo, Novosibirsk Region, 630559 Russia. kachko@vector.nsc.ru
A V
AV
Kachko
V A
VA
Sviatchenko
V A
VA
Ternovoĭ
N N
NN
Kiselev
A V
AV
Sorokin
S L
SL
Kiselev
G P
GP
Georgiev
S V
SV
Netesov
D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology; D017500:Adenovirus E1A Proteins / Q000235:genetics; D017501:Adenovirus E1B Proteins / Q000235:genetics; D000818:Animals; D001483:Base Sequence; D017931:DNA Primers; D017353:Gene Deletion; D017781:Genes, Immediate-Early; D016158:Genes, p53; D006801:Humans; D051379:Mice; D016297:Mutagenesis, Site-Directed; D014407:Tumor Cells, Cultured; D014779:Virus Replication / Q000235:genetics*
D017500:Adenovirus E1A Proteins; D017501:Adenovirus E1B Proteins; D017931:DNA Primers